Overview of Aklofep

Property	Description
Active ingredient	Aceclofenac
Form	Oral tablets (coated)
Pharmacological class	Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose	Relief of pain and inflammation
Origin	Synthetic (Chemically derived)
Status	Prescription-only (Rx) medicine

The Core Identity: What Type of Medicine is Aklofep?

Aklofep is a pharmaceutical preparation delivered as an oral tablet that is designated as a prescription-only (Rx) medicine. Its sole active ingredient is Aceclofenac, a synthetic phenylacetic acid derivative that is structurally and functionally related to other recognized analgesic compounds. It is formally classified as a Non-steroidal Anti-inflammatory Drug (NSAID), belonging to the acetic acid derivatives group. This categorization confirms its established pharmacological status as an agent designed to manage inflammatory responses. Its use is clinically recognized for providing systemic relief across adult patient groups.

Form, Origin, and Preparation

The product is a single-ingredient product presented in the form of coated oral tablets designed for systemic action following ingestion. The active substance, Aceclofenac, is a chemically synthesized compound, reinforcing its synthetic drug entity status, and is structurally derived from Diclofenac. This preparation is intended specifically for oral administration, differentiating it from topical or injectable forms of similar anti-inflammatory agents. The formulation utilizes a solid oral formulation vehicle to ensure consistent and standardized delivery of the active substance within a measured dose.

General Therapeutic Purpose

The overall therapeutic purpose of Aklofep is to provide dual-action symptomatic relief by acting as both an analgesic and an anti-inflammatory agent. Its mechanism involves targeting inflammatory pathways, thereby reducing the mediators responsible for pain and swelling. The fundamental use is the reliable alleviation of discomfort and reduction of swelling associated with systemic inflammatory conditions, a primary objective that is consistent with its established clinical profile.

What side effects are possible with Aklofep?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of Aklofep (Aceclofenac) based on the frequency and the System-Organ Class (SOC) of the documented adverse reactions.

Common adverse reactions (occurring in 1 out of 100 to 1 out of 10 people) primarily involve the gastrointestinal system and include dyspepsia, abdominal pain, nausea, and diarrhea, along with dizziness and increased hepatic enzyme levels. Uncommon reactions may include vomiting, constipation, mouth ulceration, rash, pruritus, and increased blood urea or creatinine levels.

Serious Adverse Reactions

Official safety documents highlight several serious, less frequent adverse reactions, including:

Gastrointestinal Risk: Rare, but potentially serious events such as gastrointestinal ulceration, haemorrhage, or perforation.
Cardiovascular Risk: Consistent with the NSAID class, there is a documented risk of arterial thrombotic events, such as myocardial infarction (heart attack) and stroke, listed as Very Rare.
Hypersensitivity: Rare, severe reactions, including anaphylactic shock and severe mucocutaneous skin reactions (Stevens Johnson Syndrome/Toxic Epidermal Necrolysis).

Population and Exposure Constraints

The regulatory profile includes specific safety considerations for certain groups. Older adults are noted to have an increased risk of adverse reactions, particularly serious gastrointestinal bleeding. The risk of arterial thrombotic events is also officially stated to increase with higher doses and longer duration of use. Furthermore, the drug is subject to safety limitations and is restricted in patients with established conditions such as severe hepatic failure, severe renal failure, or severe congestive heart failure.

Overdose and Emergency Response

The official regulatory documentation for Aklofep (Aceclofenac) describes overdose presentations involving primarily the gastrointestinal and central nervous systems. Documented clinical manifestations include headache, nausea, vomiting, and epigastric pain, alongside CNS effects such as drowsiness, dizziness, and occasionally convulsions. Systemic signs like hypotension and respiratory depression are also noted.

Overdose is classified by the potential for serious or life-threatening outcomes. These outcomes include the risk of acute renal failure, liver damage, and potentially fatal gastrointestinal bleeding, which is a key risk noted for all NSAIDs.

Immediate medical attention must be sought in all cases of suspected overdose.

Regulatory guidance emphasizes that management must be strictly symptomatic and supportive, as no specific antidote is known for this medicinal product. Supportive procedures officially documented include the consideration of activated charcoal or gastric lavage, depending on the time elapsed since ingestion of a potentially toxic or life-threatening amount. Furthermore, patients experiencing prolonged convulsions require treatment with intravenous diazepam. Close monitoring of renal and liver function is also mandated. Special consideration is given to the elderly and patients with pre-existing organ impairment, who are officially recognized as being at higher risk for severe or fatal overdose outcomes.

Therapeutic Uses of Aklofep

Quick Facts: Aklofep

Main Use: Managing discomfort and swelling associated with specific joint conditions.
Therapeutic Focus: Providing relief for symptoms related to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
Primary Benefit: Supports functional capacity and aids in the reduction of pain and inflammation in affected joints.

Aklofep is a prescribed medication intended for use in the management of specific conditions related to joint health and inflammation. Its primary therapeutic domains involve addressing the discomfort and swelling associated with chronic joint disorders. This medication is utilized to help relieve the symptomatic burden of conditions such as osteoarthritis, which involves joint cartilage loss, and rheumatoid arthritis, an autoimmune inflammatory disorder.

The medication is also indicated for the treatment of ankylosing spondylitis, a long-term condition that affects the spine and larger joints. It acts to reduce joint pain, stiffness, and local inflammation. In doing so, it may assist individuals in maintaining or improving their functional capacity and overall quality of life.

Aklofep is not approved for use in the United States, but it is available in other countries for its indicated purposes. The decision to incorporate Aklofep into a treatment regimen should be made by a qualified healthcare professional.

Eligibility and Restrictions for Use

Who Can and Cannot Use Aklofep? — Official Regulatory Information

Eligibility for Aklofep (Trifarotene) Cream is strictly defined by regulatory documents, focusing on age and specific pre-existing conditions.

Populations for Whom Use is Restricted or Prohibited

Classification	Who Must Not Use (Contraindicated)
Hypersensitivity	Individuals with a known allergy or hypersensitivity to the active substance Trifarotene or any of the product's inactive ingredients (excipients).
Pregnancy Status	Women who are pregnant or women planning to become pregnant. The medicine can cause harm to the fetus and is restricted for use in this population.
Age Restriction	Pediatric patients younger than 9 years of age.

Eligibility Constraints and Considerations

Minimum Age for Use:

Official labeling defines the eligible population as patients 9 years of age and older. Use in children under this age is not authorized.

Pregnancy and Fetal Risk:

While systemic absorption is generally low with topical use, the risk profile of the retinoid class necessitates a strong warning and restriction. Women who are or may become pregnant are practically excluded from treatment, and effective contraception must be used by women of childbearing potential during therapy.

Eligibility Structure:

Official documents define eligibility through a narrow age range and a mandatory exclusion for those with a known allergy. The pregnancy-related warning serves as a critical regulatory exclusion, meaning the medicine is restricted for any patient for whom this risk applies.

What should I know about interactions with other medicines?

The interaction profile for Aklofep is officially documented across several categories based on authoritative regulatory information. Co-administration is formally prohibited with other NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors, due to an increased and additive risk of severe adverse events, specifically gastrointestinal bleeding and ulceration.

The official label mandates a timing separation for Mifepristone; Aklofep must not be used for 8 to 12 days following its administration. Caution is also advised when co-administering Methotrexate within a 24-hour period due to the documented potential for increased plasma levels and toxicity.

Aklofep influences the exposure of certain medicines by reducing their renal clearance. This outcome is documented for Lithium and Cardiac Glycosides (such as Digoxin), which can result in increased serum concentrations of the co-administered drug. The interaction with oral Antidiabetic Agents has been noted in isolated reports of altered blood glucose levels.

Pharmacodynamic interactions are defined by an additive risk for serious complications. Combined use with Anticoagulants (e.g., Warfarin), Corticosteroids, and SSRIs may enhance the risk of hemorrhage or GI ulceration. Aklofep is also documented to reduce the efficacy of Diuretics and Antihypertensives while simultaneously increasing the risk of nephrotoxicity. This renal risk is officially heightened in the elderly and in patients with compromised renal function or dehydration. Additionally, co-administration with Alcohol increases the risk of gastrointestinal bleeding.

Mechanism of Action

The mechanism of Aklofep (Aceclofenac) is defined by its ability to influence specific enzyme systems and cellular pathways that mediate inflammation and nociception.

The primary action involves the preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This blockade restricts the conversion of arachidonic acid into pro-inflammatory mediators, chiefly Prostaglandin E2 ( PGE2). By suppressing PGE2 production, the drug interferes with the chemical cascade responsible for the sensitization of peripheral nociceptors and the modulation of capillary permeability.

Beyond COX inhibition, the mechanism involves the modulation of systemic inflammatory signaling. It suppresses the production of key pro-inflammatory cytokines (e.g., Interleukin-1beta) and down-regulates leukocyte adhesion molecules ( L-selectin). This reduces the physical migration of immune cells into inflamed tissues and modifies the continuation of the inflammatory signaling cycle.

Furthermore, the drug's active metabolite, 4'-hydroxyaceclofenac, contributes to local tissue regulation. This secondary action inhibits the production of destructive enzymes, such as Metalloproteinases, and stimulates the synthesis of glycosaminoglycans, influencing the regulation of the connective tissue matrix.

Dosage and Administration Information

How to Use Aklofep

Aklofep is an oral prescription medicine that requires adherence to specific administration guidelines detailed in its product information. The administration is focused on achieving systemic action using the approved 100 mg film-coated tablet formulation.

Feature	Official Administration Guideline
Route of Administration	Oral
Standard Dosing Schedule	100 mg twice daily. The maximum total daily dosage is 200 mg.
Timing and Intake	The tablet must be taken with food or immediately after a meal and swallowed whole with water. The tablet should not be crushed or chewed.

Official Usage Patterns

The official instruction for Aklofep is to use the shortest effective duration necessary for symptomatic management. This principle governs its use in chronic inflammatory conditions. For dosing frequency, the total daily amount is typically divided into two doses administered at approximately 12-hour intervals.

Population-Specific Use

Dosing requires adjustment for certain patient groups as specified in the prescribing information. For individuals diagnosed with mild-to-moderate hepatic impairment, the dosage must be reduced to 100 mg once daily. While older adults may commence treatment at the standard adult dose, careful clinical supervision is mandated.

If a dose is missed, standard instructions advise taking the next scheduled dose at the usual time; a double dose must not be taken to compensate for the forgotten dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aklofep

Evidence for Use in Osteoarthritis

Research into Aklofep's active ingredient, Aceclofenac, primarily involves short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adult patients whose condition is marked by functional limitations and outcomes related to physical discomfort. The study base for this condition is generally well-documented for the scope of the investigation.

Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the trials when compared both to inactive placebo and to active comparator medications. What remains uncertain is the full picture of the long-term effects, as follow-up durations were limited in the primary studies, meaning the durability of observed patterns extending beyond 12 weeks is not fully established.

Evidence for Use in Rheumatoid Arthritis and Ankylosing Spondylitis

Aklofep was studied for its potential role in conditions involving periods of heightened symptoms, such as Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). For these indications, the research base includes RCTs and clinical reviews. These studies monitored outcomes linked to inflammatory states, such as joint swelling and the duration of morning stiffness. The research base for these indications is available for review but is less extensive than the research for Osteoarthritis.

However, the evidence is limited compared to the research available for Osteoarthritis. The research primarily focuses on symptom measurement and relies on comparisons to active agents, which results in findings describing relative patterns, rather than absolute ones. Long-term effects are not fully established, and data are still emerging regarding the sustained use of the medicine beyond the short-term window.

Evidence in Special and Diverse Populations

The majority of the clinical trial data was collected in general adult populations with specific inflammatory conditions. Data for certain groups remain insufficient. While older adults are observed in the broader patient groups studied, dedicated research exploring the use in children is not available, nor is research focusing on patients with specific comorbid conditions typically addressed in the primary regulatory documentation. The results apply only to the populations studied.

What Is Still Uncertain About the Research Base

Several research limitation frames apply across the evidence base. Follow-up durations were limited in the major efficacy trials, meaning long-term effects are not fully established. Evidence quality varies across studies, and sample sizes were modest in some of the non-arthritic pain trials, contributing to uncertainty in those specific findings. Evidence highlights what is known—and what is still uncertain—and findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Aklofep (FAQ)

Q: How quickly should I expect Aklofep to start working?

A: Aklofep is an NSAID intended for symptomatic relief. Clinical profiles suggest relief may become noticeable within the first week for many patients, though achieving the full therapeutic effect in chronic conditions may require longer. Individual response times can vary.

Q: Does Aklofep make you sleepy or affect energy levels?

A: Regulatory documents indicate that Aklofep may cause side effects related to the central nervous system, such as dizziness and drowsiness (somnolence). Experiencing these effects may necessitate caution regarding activities like driving or operating machinery, as these functions may be impaired.

Q: Are there any specific foods or drinks to avoid while taking Aklofep?

A: Official regulatory documents explicitly warn against consuming alcohol while taking Aklofep, as this combination significantly increases the risk of serious gastrointestinal bleeding. The medicine is also mandated to be taken with food or immediately following a meal.

Q: Can Aklofep be taken long-term?

A: Official guidelines emphasize that, consistent with the NSAID class, Aklofep should be used at the lowest effective dose for the shortest duration possible. Regulatory guidance indicates that the cardiovascular risks associated with the NSAID class may increase with higher doses and duration of exposure.

Q: Does Aklofep cause stomach issues or nausea?

A: Yes, regulatory safety profiles list nausea and abdominal pain as common gastrointestinal adverse reactions. The official safety profile notes rare but serious potential risks for the NSAID class, including gastrointestinal ulceration, bleeding, and perforation.

Q: Are there any studies about Aklofep's effectiveness for its stated purpose?

A: Yes, the effectiveness of Aklofep is supported by controlled clinical research. Official product information is based on short-term Randomized Controlled Trials (RCTs) demonstrating effectiveness in managing symptoms associated with conditions like Osteoarthritis and Rheumatoid Arthritis.

Q: Can Aklofep raise blood pressure?

A: Official warnings state that the drug can reduce the efficacy of blood pressure medicines (antihypertensives). NSAID use may also be associated with new-onset hypertension (high blood pressure) or worsening of an existing condition.

Q: Is it true that Aklofep can cause dizziness?

A: Yes, this is correct. Dizziness is a documented adverse reaction to Aklofep, listed in regulatory sources as a common side effect. Because dizziness is a documented side effect, caution may be necessary when performing tasks that require mental alertness, such as driving.

Q: Does Aklofep affect liver function tests?

A: Official safety data confirms that Aklofep can result in an increase in hepatic enzyme levels, which are measured by liver function tests. This effect is listed as a common reaction and may require monitoring of liver function during the course of treatment.

Q: Is it normal to feel a slight headache when first starting Aklofep?

A: Headache is a known side effect reported with medicines in the NSAID class, though it is not always listed as a 'common' side effect in the primary documentation. If you experience a new or persistent headache after starting the medicine, it is a symptom that should be noted.

Q: Is there a generic version of Aklofep available?

A: Aklofep is a brand name for the active ingredient Aceclofenac. Aceclofenac is available under various brand names and as a generic medicine in many regions globally, following standard regulatory approvals.

Q: Is Aklofep safe to take if I have kidney problems?

A: Aklofep is contraindicated (must not be used) in patients with severe renal failure. Caution is also strongly advised for patients with existing mild-to-moderate kidney impairment, as the medicine can increase the risk of kidney-related issues (nephrotoxicity).

Q: Does Aklofep need to be taken with food?

A: Yes, official instructions state that the tablet must be taken with food or immediately following a meal and swallowed whole with water. This method of administration is specified in the regulatory labeling.

Q: Can Aklofep cause changes in mood or anxiety?

A: Side effects affecting the Central Nervous System (CNS), such as dizziness, are documented. While changes in mood or anxiety are generally not common, regulatory documents have rarely associated this class of medicine with psychological effects.

Q: Can Aklofep cause difficulty sleeping?

A: Adverse effects on the nervous system are documented for Aklofep. Although infrequent, conditions like insomnia (difficulty sleeping) have been reported in regulatory documents for this class of medicine.

Q: Does using Aklofep affect the immune system?

A: Aklofep is classified as an NSAID and is not an immunosuppressant. It works by suppressing key inflammatory mediators, such as cytokines, which are components of the inflammatory response. This action modifies how the body responds to inflammation.

Q: Is Aklofep addictive?

A: No. Aklofep is an NSAID and is not scheduled as a controlled substance by regulatory bodies. It is not associated with the abuse potential or physical dependence risk found with addictive medications.

Q: Does Aklofep make you more sensitive to the sun?

A: An increased sensitivity to sunlight, known as photosensitivity, has been documented in regulatory sources as a potential dermatological side effect. If this side effect occurs, limiting sun exposure is generally recommended.

Q: What is the maximum duration of use cited in clinical research for Aklofep?

A: Regulatory guidance emphasizes that the medicine should be used for the shortest duration possible to achieve symptomatic relief. Clinical trials supporting its use in chronic conditions have typically been limited to around 12 weeks.

Q: Are there different strengths of Aklofep available?

A: The strength of Aklofep most commonly available and approved for the standard adult dosing regimen is the 100 mg film-coated tablet.

How should Aklofep be stored and disposed of?

How to Store and Dispose of Aklofep?

Official regulatory documentation defines specific requirements for storing, handling, and disposing of Aklofep to ensure its stability and prevent environmental risks.

Storage and Stability Requirement	Official Guidance
Temperature	Store below 30°C. Do not freeze.
Environmental Protection	Keep in the original outer carton to protect from light and moisture.
Child Safety	Keep out of the sight and reach of children.
In-Use Stability	After first opening, the product must be used within 28 days.
Disposal	Do not dispose of via household waste or wastewater. Return any unused or expired medicine to a pharmacist or local drug take-back program for proper disposal.

Aklofep